Patents by Inventor Belinda Huff

Belinda Huff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11884673
    Abstract: Compounds useful in the modulation of ion channel activity in cells are disclosed herein. This disclosure also relates to use of these compounds in the treatment of pain, and pharmaceutical compositions containing these compounds and methods for their preparation.
    Type: Grant
    Filed: April 20, 2022
    Date of Patent: January 30, 2024
    Assignee: BIONOMICS LIMITED
    Inventors: Belinda Huff, Courtney Hollis, Hamish Toop, Nathan Kuchel, Lorna Helen Mitchell, Rajinder Singh
  • Publication number: 20220251099
    Abstract: Compounds useful in the modulation of ion channel activity in cells are disclosed herein. This disclosure also relates to use of these compounds in the treatment of pain, and pharmaceutical compositions containing these compounds and methods for their preparation.
    Type: Application
    Filed: April 20, 2022
    Publication date: August 11, 2022
    Inventors: Belinda HUFF, Courtney HOLLIS, Hamish TOOP, Nathan KUCHEL, Lorna Helen MITCHELL, Rajinder SINGH
  • Patent number: 11384085
    Abstract: Compounds useful in the modulation of ion channel activity in cells are disclosed herein. This disclosure also relates to use of these compounds in the treatment of pain, and pharmaceutical compositions containing these compounds and methods for their preparation.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: July 12, 2022
    Assignee: BIONOMICS LIMITED
    Inventors: Belinda Huff, Courtney Hollis, Hamish Toop, Nathan Kuchel, Lorna Helen Mitchell, Rajinder Singh
  • Publication number: 20210355124
    Abstract: The present invention relates generally to chemical compounds of formula (I) and methods for their use and preparation. In particular, the invention relates to chemical compounds which are useful in relation to the treatment of diseases, disorders or conditions which would benefit from the modulation of the alpha 7 nicotinic acetylcholine receptor (?7 nAChR), such as anxiety, depression and stress related disorders.
    Type: Application
    Filed: October 18, 2019
    Publication date: November 18, 2021
    Inventors: Lorna Mitchell, Hamish Toop, Belinda Huff, Justin Ripper, Rajinder Singh, Christophe Morice, Jean-Marie Contreras, Patrick Bazzini, Laurent Schaeffer, Mathieu Michaut
  • Publication number: 20210230165
    Abstract: Compounds useful in the modulation of ion channel activity in cells are disclosed herein. This disclosure also relates to use of these compounds in the treatment of pain, and pharmaceutical compositions containing these compounds and methods for their preparation.
    Type: Application
    Filed: May 17, 2019
    Publication date: July 29, 2021
    Inventors: Belinda HUFF, Courtney HOLLIS, Hamish TOOP, Nathan KUCHEL, Lorna Helen MITCHELL, Rajinder SINGH
  • Publication number: 20210230157
    Abstract: The present invention relates to compounds useful in the modulation of ion channel activity in cells. The invention also relates to use of these compounds in the treatment of pain, and pharmaceutical compositions containing these compounds and methods for their preparation.
    Type: Application
    Filed: May 17, 2019
    Publication date: July 29, 2021
    Inventors: Belinda HUFF, Courtney HOLLIS, Hamish TOOP, Nathan KUCHEL, Lorna Helen MITCHELL, Rajinder SINGH, Thomas AVERY, Celine MICHAUT-SIMON, Jean-Marie CONTRERAS, Christophe MORICE
  • Patent number: 9994518
    Abstract: Disclosed are compounds of Formula (IVA), or a salt thereof, and pharmaceutical formulations (pharmaceutical compositions) comprising those compounds, or a salt thereof: Formula (IVA), wherein “RIa”, “RIb”, “RIc”, “RId”, “RIe”, are defined herein above, which compounds are believed suitable for use in positive modulation of the alpha 7 nicotinic acetylcholine receptor (?7 nAChR) receptors, for example, those found in the cerebral cortex and the hippocampus. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Alzheimer's disease (AD), schizophrenia, and Parkinson's disease (PD), or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: June 12, 2018
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Kenneth Leavitt, Brendan Crowley, Ian M. Bell, Andrew Harvey, Thomas Avery, Dharam Paul, Justin Ripper, Belinda Huff, Rajinder Singh, Laurent Schaeffer, Christophe Joseph, Christophe Morice, Bruno Giethlen, Patrick Bazzini, Aurelie Fromeyer
  • Patent number: 9790173
    Abstract: The present invention relates to chemical compounds of formula (I), with the substituents as described in the specification, useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (?7 nAChR). The invention also relates to the use of these compounds in the treatment or prevention of a broad range of diseases in which the positive modulation of ?7 nAChR is advantageous, including neurodegenerative and neuropsychiatric diseases and also neuropathic pain and inflammatory diseases.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: October 17, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Andrew Harvey, Thomas Avery, Dharam Paul, Justin Ripper, Belinda Huff, Rajinder Singh, Laurent Schaeffer, Christophe Joseph, Christophe Morice, Bruno Giethlen
  • Publication number: 20170158628
    Abstract: The present invention relates to chemical compounds of formula (I), with the substituents as described in the specification, useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (?7 nAChR). The invention also relates to the use of these compounds in the treatment or prevention of a broad range of diseases in which the positive modulation of ?7 nAChR is advantageous, including neurodegenerative and neuropsychiatric diseases and also neuropathic pain and inflammatory diseases.
    Type: Application
    Filed: February 17, 2017
    Publication date: June 8, 2017
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: ANDREW HARVEY, THOMAS AVERY, DHARAM PAUL, JUSTIN RIPPER, BELINDA HUFF, RAJINDER SINGH, LAURENT SCHAEFFER, CHRISTOPHE JOSEPH, CHRISTOPHE MORICE, BRUNO GIETHLEN
  • Publication number: 20170152221
    Abstract: Disclosed are compounds of Formula (IVA), or a salt thereof, and pharmaceutical formulations (pharmaceutical compositions) comprising those compounds, or a salt thereof: Formula (IVA), wherein “RIa”, “RIb”, “RIc”, “RId”, “RIe”, are defined herein above, which compounds are believed suitable for use in positive modulation of the alpha 7 nicotinic acetylcholine receptor (?7 nAChR) receptors, for example, those found in the cerebral cortex and the hippocampus. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Alzheimer's disease (AD), schizophrenia, and Parkinson's disease (PD), or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.
    Type: Application
    Filed: June 11, 2015
    Publication date: June 1, 2017
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: KENNETH LEAVITT, BRENDAN CROWLEY, IAN M. BELL, ANDREW HARVEY, THOMAS AVERY, DHARAM PAUL, JUSTIN RIPPER, BELINDA HUFF, RAJINDER SINGH, LAURENT SCHAEFFER, CHRISTOPHE JOSEPH, CHRISTOPHE MORICE, BRUNO GIETHLEN, PATRICK BAZZINI, AURELIE FROMEYER
  • Patent number: 9593096
    Abstract: The present invention relates to chemical compounds useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (?7 nAChR).
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: March 14, 2017
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Andrew Harvey, Belinda Huff, Rajinder Singh, Nathan Kuchel
  • Publication number: 20160075684
    Abstract: The present invention relates to chemical compounds useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (?7 nAChR).
    Type: Application
    Filed: April 24, 2014
    Publication date: March 17, 2016
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Andrew Harvey, Belinda Huff, Rajinder Singh, Nathan Kuchel
  • Publication number: 20150175534
    Abstract: The present invention relates to chemical compounds of formula (I), with the substituents as described in the specification, useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (?7 nAChR). The invention also relates to the use of these compounds in the treatment or prevention of a broad range of diseases in which the positive modulation of ?7 nAChR is advantageous, including neurodegenerative and neuropsychiatric diseases and also neuropathic pain and inflammatory diseases.
    Type: Application
    Filed: August 1, 2013
    Publication date: June 25, 2015
    Inventors: Andrew Harvey, Thomas Avery, Dharam Paul, Justin Ripper, Belinda Huff, Rajinder Singh, Laurent Schaeffer, Christophe Joseph, Christophe Morice, Bruno Giethlen